EANM procedure guideline for radio-immunotherapy for B-cell lymphoma with 90Y-radiolabelled ibritumomab tiuxetan (Zevalin)
EANM procedure guideline for radio-immunotherapy for B-cell lymphoma with 90Y-radiolabelled ibritumomab tiuxetan (Zevalin)
复制标题
DOI：
10.1007/s00259-007-0372-y
复制
发表时间：
2007-04-01
影响因子：
9.1
通讯作者：
Brans, Boudewijn
中科院分区：
文献类型：
--
作者：
Tennvall, Jan;Fischer, Manfred;Brans, Boudewijn
背景 2004 年 1 月，EMEA 在欧洲批准了 Y-90 放射性标记的 ibritumomab tiuxetan（Zevalin）用于治疗利妥昔单抗复发或难治性 CD20+ 滤泡 B 细胞非霍奇金淋巴瘤成人患者。使用 Zevalin 的欧洲核医学科室数量不断增加，因为这种疗法通常被认为是成功的。治疗、肿瘤和剂量测定委员会共同努力，制定了一些关于 Zevalin 使用的 EANM 指南，特别关注与核医学相关的问题。 目的 本指南的目的是协助核医学医师治疗和管理可能适合放射免疫治疗的患者。该指南还强调需要与治疗患者潜在疾病的医生密切合作。
Background In January 2004, EMEA approved Y-90-radiolabelled ibritumomab tiuxetan, Zevalin, in Europe for the treatment of adult patients with rituximab-relapsed or -refractory CD20+ follicular B-cell non-Hodgkin's lymphoma. The number of European nuclear medicine departments using Zevalin is continuously increasing, since the therapy is often considered successful. The Therapy, Oncology and Dosimetry Committees have worked together in order to define some EANM guidelines on the use of Zevalin, paying particular attention to the problems related to nuclear medicine.Purpose The purpose of this guideline is to assist the nuclear medicine physician in treating and managing patients who may be candidates for radio-immunotherapy. The guideline also stresses the need for close collaboration with the physician(s) treating the patient for the underlying disease.